Dtsch Med Wochenschr 2020; 145(04): 232-239
DOI: 10.1055/a-0974-8418
© Georg Thieme Verlag KG Stuttgart · New York

C3-Glomerulopathie und MPGN – aktuelle Klassifikationen

C3 glomerulopathy and MPGN – current classification
Bernd Hohenstein
Further Information

Publication History

Publication Date:
18 February 2020 (online)


Membranoproliferative glomerulonephritis (MPGN) and glomerulopathy with dominant C3 deposits are very rare autoimmune disorders of the kidney that had been classified in its current form in 2010 due to a better understanding of the underlying pathophysiology.

Today, the immune complex-associated membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) represent a disease spectrum which is heterogeneous in terms of pathophysiology and the clinical time course. Interestingly, recent research demonstrated more common pathophysiological aspects with respect to secondary causes, autoantibodies, and genetics of IC-MPGN and C3G than it had been suggested with the creation of the 2010 classification.

This knowledge of the underlying pathophysiology is of specific importance for the identification of potential secondary causes. Therefore, following histologic diagnosis a comprehensive complement analysis, accompanied by antibody screening and human genetics should be carried out consistently. The published evidence provides a robust basis for the use of available therapeutic approaches for these often rapidly progressive and relapsing diseases.

Sehr selten wird bei Patienten die Diagnose einer C3-Glomerulopathie oder membranoproliferativen Glomerulonephritis gestellt. Durch die Relevanz des Komplementsystems für diese Erkrankungen ist die Kenntnis der Pathophysiologie von großer Bedeutung. Dieser Beitrag trägt aktuelle Entwicklungen zum Verständnis dieser Krankheitsbilder zusammen und soll Hilfestellung bei der Aufarbeitung entsprechender Fälle geben.

  • Literatur

  • 1 Hohenstein B, Licht C, Wiesener M. et al. „State-of-the-art“: C3-Glomerulopathie und membranoproliferative Glomerulonephritis. Nephrologe 2015; 10: 327-340
  • 2 Goodship TH, Cook HT, Fakhouri F. et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a „Kidney Disease: Improving Global Outcomes“ (KDIGO) Controversies Conference. Kidney Int 2017; 91: 539-551
  • 3 Pickering MC, D'Agati VD, Nester CM. et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089
  • 4 Marinozzi MC, Roumenina LT, Chauvet S. et al. Anti-factor B and Anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN. J Am Soc Nephrol 2017; 28: 1603-1613
  • 5 Zhang Y, Meyer NC, Fervenza FC. et al. C4 Nephritic factors in C3 glomerulopathy: A case series. Am J Kidney Dis 2017; 70: 834-843
  • 6 Marinozzi MC, Chauvet S, Le Quintrec M. et al. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 2017; 92: 1232-1241
  • 7 Hou J, Markowitz GS, Bomback AS. et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014; 85: 450-456
  • 8 Ravindran A, Fervenza FC, Smith RJH. et al. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 2018; 94: 178-186
  • 9 Smith RJ, Alexander J, Barlow PN. et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456
  • 10 Medjeral-Thomas NR, O'Shaughnessy M, O'Regan JA. et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014; 9: 46-53
  • 11 Servais A, Noel LH, Roumenina LT. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464
  • 12 Klein RJ, Zeiss C, Chew EY. et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389
  • 13 Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83: 18-34
  • 14 Iatropoulos P, Daina E, Curreri M. et al. Cluster Analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol 2018; 29: 283-294
  • 15 Iatropoulos P, Noris M, Mele C. et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 2016; 71: 131-142
  • 16 Hohenstein B, Grählert X, Hugo C. Neues Register für C3‑Glomerulopathie und Immunkomplex-vermittelte MPGN (C3G‑Register). Nephrologe 2015; 10: 1-2
  • 17 Mollnes TE, Jokiranta TS, Truedsson L. et al. Complement analysis in the 21st century. Mol Immunol 2007; 44: 3838-3849
  • 18 Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol 2019; 34 (08) 1311-1323
  • 19 Sethi S, Gamez JD, Vrana JA. et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960
  • 20 Muczynski KA. Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Am J Nephrol 1995; 15: 446-449
  • 21 Rabasco C, Cavero T, Román E. et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015; 88: 1153-1160
  • 22 Avasare RS, Canetta PA, Bomback AS. et al. Mycophenolate Mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 2018; 13: 406-413
  • 23 Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol 2016; 28: 208-222
  • 24 Welte T, Arnold F, Kappes J. et al. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018; 19: 7